Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS 4	AUG 11	STN AnaVist workshops to be held in North America
NEWS 5	AUG 30	CA/CAplus -Increased access to 19th century research documents
NEWS 6	AUG 30	CASREACT - Enhanced with displayable reaction conditions
NEWS 7	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 8	OCT 03	MATHDI removed from STN
NEWS 9	OCT 04	CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS 10	OCT 06	STN AnaVist workshops to be held in North America
NEWS 11	OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS 12	OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools

NEWS EXPRESS	JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:57:51 ON 21 OCT 2005

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:58:05 ON 21 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 OCT 2005 HIGHEST RN 865652-03-5
DICTIONARY FILE UPDATES: 19 OCT 2005 HIGHEST RN 865652-03-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10502380.str



chain nodes :
13 14 15 16 17 18 19 20 21 22 23 24
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
1-14 3-13 6-19 12-15 14-22 14-23 14-24 15-16 16-17 16-18 19-20 19-21
ring bonds :
1-2 1-7 2-3 3-4 4-8 5-6 5-9 5-12 6-7 7-8 8-9 9-10 10-11 11-12
exact/norm bonds :
1-14 5-6 5-9 5-12 6-7 6-19 8-9 9-10 10-11 11-12 14-22 14-23
exact bonds :
3-13 12-15 14-24 15-16 19-20 19-21
normalized bonds :
1-2 1-7 2-3 3-4 4-8 7-8 16-17 16-18
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 12:58:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        2 TO ITERATE

100.0% PROCESSED         2 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:             2 TO      124
PROJECTED ANSWERS:                0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 12:58:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       46 TO ITERATE

100.0% PROCESSED        46 ITERATIONS                               8 ANSWERS
SEARCH TIME: 00.00.01

L3             8 SEA SSS FUL L1

=> FIL HCAPLUS
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     161.33     161.54

FILE 'HCAPLUS' ENTERED AT 12:58:35 ON 21 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 21 Oct 2005 VOL 143 ISS 18
FILE LAST UPDATED: 20 Oct 2005 (20051020/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 4 L3

=> d l4 ibib abs hitstr tot

L4 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:1052400 HCAPLUS
DOCUMENT NUMBER: 142:155766
TITLE: Asymmetric Synthesis of a Prostaglandin D2 Receptor Antagonist
AUTHOR(S): Campos, Kevin R.; Journet, Michel; Lee, Sandra; Grabowski, Edward J. J.; Tillyer, Richard D.
CORPORATE SOURCE: Department of Process Research, Merck Research Laboratories, Rahway, NJ, 07065-0900, USA
SOURCE: Journal of Organic Chemistry (2005), 70(1), 268-274
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:155766
GI



I

AB An asym. synthesis was developed for the production of a prostaglandin D2

receptor antagonist (I) for the treatment of allergic rhinitis. The stereogenic center was set using asym. allylic alkylation chemical, and the core of the structure was constructed via Pd-catalyzed N-cyclization/Heck methodol. The synthesis relies on a late stage indoline oxidation which does not racemize the product.

IT **571170-77-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(asym. preparation of [(3R)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid as a prostaglandin D2 receptor antagonist)

RN 571170-77-9 HCAPLUS

CN Cyclopent[b]indole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:1040450 HCAPLUS

DOCUMENT NUMBER: 142:429673

TITLE: Base-catalyzed deuterium and tritium labeling of aryl methyl sulfones

AUTHOR(S): Scheigetz, John; Berthelette, Carl; Li, Chun; Zamboni, Robert J.

CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Frosst Centre for Therapeutic Research, Pointe-Claire/Dorval, QC, H9R 4P8, Can.

SOURCE: Journal of Labelled Compounds & Radiopharmaceuticals (2004), 47(12), 881-889
CODEN: JLCRD4; ISSN: 0362-4803

PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A method is presented for conveniently tritiating the aryl Me sulfones of compds. identified as potent and selective inhibitors of human Cox-2 and as DP receptor antagonists. A base-catalyzed exchange reaction was conducted with deuterated water and the total deuterium incorporation, ranging from 46 to 99%, was calculated using mass spectrometry. Results from these exchanges were used as guidelines for tritium labeling giving specific radioactivities in the range of 28-120 mCi/mmol (1.03-4.43 GBq/mmol).

IT **850896-73-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(base-catalyzed deuterium and tritium labeling of aryl Me sulfones)

RN 850896-73-0 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-(2-benzothiazolylmethyl)-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **850896-73-0DP**, tritiated **850896-78-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(base-catalyzed deuterium and tritium labeling of aryl Me sulfones)
RN 850896-73-0 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-(2-benzothiazolylmethyl)-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850896-78-5 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-(2-benzothiazolylmethyl)-7-fluoro-1,2,3,4-tetrahydro-5-(methyl-d3-sulfonyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:999670 HCAPLUS
DOCUMENT NUMBER: 141:420447
TITLE: Method of treating atherosclerosis, dyslipidemias and related conditions
INVENTOR(S): Cheng, Kang; Waters, M. Gerard; Metters, Kathleen M.; O'Neill, Gary
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 33 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004229844	A1	20041118	US 2004-844773	20040513
WO 2004103370	A1	20041202	WO 2004-US14980	20040513

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-470665P P 20030515

AB A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent or eliminate flushing that may otherwise occur.

IT **571170-77-9P 571170-79-1P 571170-95-1P**
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(method of treating atherosclerosis, dyslipidemias and related conditions)

RN 571170-77-9 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 571170-79-1 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 9-[(4-chlorophenyl)methyl]-6-fluoro-2,3,4,9-tetrahydro-8-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 571170-95-1 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-1-oxo-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **572874-50-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(method of treating atherosclerosis, dyslipidemias and related conditions)
RN 572874-50-1 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, sodium salt, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● Na

L4 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:591147 HCAPLUS
DOCUMENT NUMBER: 139:149524
TITLE: Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment using them
INVENTOR(S): Berthelette, Carl; Lachance, Nicolas; Li, Lianhai; Sturino, Claudio; Wang, Zhaoyin
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062200	A2	20030731	WO 2003-CA84	20030122
WO 2003062200	A3	20031204		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003158246	A1	20030821	US 2003-348403	20030121

CA 2471952	AA	20030731	CA 2003-2471952	20030122
BR 2003007050	A	20041026	BR 2003-7050	20030122
EP 1470107	A2	20041027	EP 2003-700740	20030122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005124680	A1	20050609	US 2003-502380	20030122
JP 2005518413	T2	20050623	JP 2003-562082	20030122
PRIORITY APPLN. INFO.:			US 2002-351384P	P 20020124
			WO 2003-CA84	W 20030122

OTHER SOURCE(S): MARPAT 139:149524
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Fluoro substituted cycloalkanoindole derivs. I [X1 = (O)n; X2 = (CH2)m; n = 0, 1; m = 1 - 3; R1 = H, C1-3-alkyl, C1-3-haloalkyl, cyclopropyl; R2 = C6H4Cl-4, C6H2Cl3-2,4,6], their enantiomers and pharmaceutically acceptable salts, are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases. Thus, (-)-cyclopentanoindole II was prepared via cyclocondensation of 4-F-2-IC6H3NH2 with Et 2-(2-oxocyclopentyl)acetate, saponification, regioselective bromination, N-alkylation with 4-ClC6H4CH2Br, resolution with (S)-(-)-1-(1-naphthyl)ethylamine, esterification with diazomethane, sulfonylation with MeSO2Na and ester hydrolysis. The binding activity of I for prostaglandin receptors was determined (no data).

IT **571170-77-9P 571170-79-1P 571170-80-4P**
571170-81-5P 571170-95-1P 572874-50-1P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and prostaglandin receptor binding activity of fluoro substituted cycloalkanoindoles)

RN 571170-77-9 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 571170-79-1 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 9-[(4-chlorophenyl)methyl]-6-fluoro-2,3,4,9-tetrahydro-8-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 571170-80-4 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-1-oxo- (9CI) (CA INDEX NAME)



RN 571170-81-5 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 571170-95-1 HCAPLUS

CN Cyclopent[b]indole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-1-oxo-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 572874-50-1 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, sodium salt, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● Na

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	27.11	188.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.92	-2.92

FILE 'REGISTRY' ENTERED AT 13:00:34 ON 21 OCT 2005

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 OCT 2005 HIGHEST RN 865652-03-5
DICTIONARY FILE UPDATES: 19 OCT 2005 HIGHEST RN 865652-03-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10502380a.str



chain nodes :
13 14 15 16 17 18 19 20
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
1-13 12-14 13-18 13-19 13-20 14-15 15-16 15-17
ring bonds :
1-2 1-7 2-3 3-4 4-8 5-6 5-9 5-12 6-7 7-8 8-9 9-10 10-11 11-12

exact/norm bonds :
1-13 5-6 5-9 5-12 6-7 8-9 9-10 10-11 11-12 13-18 13-19
exact bonds :
12-14 13-20 14-15
normalized bonds :
1-2 1-7 2-3 3-4 4-8 7-8 15-16 15-17
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l5
SAMPLE SEARCH INITIATED 13:00:55 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4 TO 200
PROJECTED ANSWERS: 2 TO 124

L6 2 SEA SSS SAM L5

```
=> s l5 sss full
FULL SEARCH INITIATED 13:01:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       61 TO ITERATE

100.0% PROCESSED       61 ITERATIONS                          32 ANSWERS
SEARCH TIME: 00.00.01

L7           32 SEA SSS FUL L5

=> FIL HCAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   161.33     349.98

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -2.92

FILE 'HCAPLUS' ENTERED AT 13:01:09 ON 21 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 21 Oct 2005  VOL 143 ISS 18
FILE LAST UPDATED: 20 Oct 2005  (20051020/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l7
L8            6 L7

=> d l8 ibib abs hitstr tot

L8   ANSWER 1 OF 6  HCAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:        2005:540567  HCAPLUS
DOCUMENT NUMBER:         143:59820
TITLE:                   Preparation of tetrahydrocarbazole and
                         cyclopentanoindole derivatives as antagonists of
                         prostaglandin D2 receptor
INVENTOR(S):             Beaulieu, Christian; Guay, Daniel; Wang, Zhaoyin;
                         Zamboni, Robert
PATENT ASSIGNEE(S):      Merck Frosst Canada & Co., Can.
SOURCE:                  PCT Int. Appl., 37 pp.
                         CODEN: PIXXD2
```

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005056527	A1	20050623	WO 2004-CA2123	20041213

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005154044	A1	20050714	US 2004-7009	20041208
PRIORITY APPLN. INFO.:			US 2003-530298P	P 20031215

OTHER SOURCE(S): MARPAT 143:59820
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [n = 0-1; R1 = H, halo; R2 = halo, cyano, alkylsulfonyl, etc.; R3 = (un)substituted alkyl; R4a and R4b are each H or one is H and the other is OH, or both together are oxo with provisions] and their pharmaceutically acceptable salts, are prepared and disclosed as antagonists of prostaglandin D2 receptor. Thus, e.g., II was prepared by esterification of [(1R)-9-[(1S)-1-(4-chlorophenyl)ethyl]-6-fluoro-8-(methylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-1-yl]acetic acid (preparation given) with methanol followed by coupling under Mitsunobu conditions with (1R)-1-[4-(trifluoromethyl)phenyl]ethanol and subsequent hydrolysis. The activity of I towards DP, CRTH2 and IP can be evaluated in prostanoid receptor binding assays utilizing HEK 293(ebna) cells (no data given). I as antagonists of prostaglandin D2 receptor should prove useful in the treatment of diseases such as rhinitis, asthma and nasal congestion. Pharmaceutical compns. comprising I are disclosed.

IT **854738-63-9P 854738-64-0P 854738-65-1P**
854738-66-2P 854738-67-3P 854738-68-4P
854738-69-5P 854738-70-8P 854738-71-9P
854738-72-0P 854738-73-1P 854738-74-2P
854738-75-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydrocarbazole and cyclopentanoindole derivs. as antagonists of prostaglandin D2 receptor)

RN 854738-63-9 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 6-fluoro-2,3,4,9-tetrahydro-8-(methylsulfonyl)-9-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 854738-64-0 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 9-[(1S)-1-(3,4-dichlorophenyl)ethyl]-6-fluoro-2,3,4,9-tetrahydro-8-(methylsulfonyl)-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 854738-65-1 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 6-fluoro-2,3,4,9-tetrahydro-8-(methylsulfonyl)-9-[(1S)-1-phenylethyl]-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 854738-66-2 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 6-fluoro-9-[(1S)-1-(4-fluorophenyl)ethyl]-2,3,4,9-tetrahydro-8-(methylsulfonyl)-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 854738-67-3 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 9-[(1S)-1-(4-chloro-3-fluorophenyl)ethyl]-6-fluoro-2,3,4,9-tetrahydro-8-(methylsulfonyl)-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 854738-68-4 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 9-[(1S)-1-(3-chlorophenyl)ethyl]-6-fluoro-2,3,4,9-tetrahydro-8-(methylsulfonyl)-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 854738-69-5 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 9-[(1S)-1-(4-chloro-2-fluorophenyl)ethyl]-6-fluoro-2,3,4,9-tetrahydro-8-(methylsulfonyl)-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 854738-70-8 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 9-[(1S)-1-(4-bromophenyl)ethyl]-6-fluoro-2,3,4,9-tetrahydro-8-(methylsulfonyl)-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 854738-71-9 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 9-[(1S)-1-(4-cyanophenyl)ethyl]-6-fluoro-2,3,4,9-tetrahydro-8-(methylsulfonyl)-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 854738-72-0 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 6-fluoro-2,3,4,9-tetrahydro-8-(methylsulfonyl)-9-[(1S)-1-[4-(methylsulfonyl)phenyl]ethyl]-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 854738-73-1 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 6-fluoro-2,3,4,9-tetrahydro-8-(methylsulfonyl)-4-oxo-9-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 854738-74-2 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 6-fluoro-2,3,4,9-tetrahydro-4-hydroxy-8-(methylsulfonyl)-9-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]-, (1R,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 854738-75-3 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 6-fluoro-2,3,4,9-tetrahydro-4-hydroxy-8-(methylsulfonyl)-9-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]-, (1R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **794535-38-9P 854738-76-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tetrahydrocarbazole and cyclopentanoindole derivs. as antagonists of prostaglandin D2 receptor)
RN 794535-38-9 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 9-[(1S)-1-(4-chlorophenyl)ethyl]-6-fluoro-2,3,4,9-tetrahydro-8-(methylsulfonyl)-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 854738-76-4 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 9-[(1S)-1-(4-chlorophenyl)ethyl]-6-fluoro-2,3,4,9-tetrahydro-8-(methylsulfonyl)-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:1052400 HCAPLUS
DOCUMENT NUMBER: 142:155766
TITLE: Asymmetric Synthesis of a Prostaglandin D2 Receptor Antagonist
AUTHOR(S): Campos, Kevin R.; Journet, Michel; Lee, Sandra; Grabowski, Edward J. J.; Tillyer, Richard D.
CORPORATE SOURCE: Department of Process Research, Merck Research Laboratories, Rahway, NJ, 07065-0900, USA
SOURCE: Journal of Organic Chemistry (2005), 70(1), 268-274
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:155766
GI



I

AB An asym. synthesis was developed for the production of a prostaglandin D2 receptor antagonist (I) for the treatment of allergic rhinitis. The stereogenic center was set using asym. allylic alkylation chemical, and the core of the structure was constructed via Pd-catalyzed N-cyclization/Heck

methodol. The synthesis relies on a late stage indoline oxidation which does not racemize the product.

IT **571170-77-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(asym. preparation of [(3R)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid as a prostaglandin D2 receptor antagonist)
RN 571170-77-9 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:1040450 HCAPLUS
DOCUMENT NUMBER: 142:429673
TITLE: Base-catalyzed deuterium and tritium labeling of aryl methyl sulfones
AUTHOR(S): Scheigetz, John; Berthelette, Carl; Li, Chun; Zamboni, Robert J.
CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Frosst Centre for Therapeutic Research, Pointe-Claire/Dorval, QC, H9R 4P8, Can.
SOURCE: Journal of Labelled Compounds & Radiopharmaceuticals (2004), 47(12), 881-889
CODEN: JLCRD4; ISSN: 0362-4803
PUBLISHER: John Wiley & Sons Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A method is presented for conveniently tritiating the aryl Me sulfones of compds. identified as potent and selective inhibitors of human Cox-2 and as DP receptor antagonists. A base-catalyzed exchange reaction was conducted with deuterated water and the total deuterium incorporation, ranging from 46 to 99%, was calculated using mass spectrometry. Results from these exchanges were used as guidelines for tritium labeling giving specific radioactivities in the range of 28-120 mCi/mmol (1.03-4.43 GBq/mmol).

IT **850896-73-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(base-catalyzed deuterium and tritium labeling of aryl Me sulfones)
RN 850896-73-0 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-(2-benzothiazolylmethyl)-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **850896-73-0DP**, tritiated **850896-78-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(base-catalyzed deuterium and tritium labeling of aryl Me sulfones)
RN 850896-73-0 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-(2-benzothiazolylmethyl)-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850896-78-5 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-(2-benzothiazolylmethyl)-7-fluoro-1,2,3,4-tetrahydro-5-(methyl-d3-sulfonyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:1037073 HCAPLUS
DOCUMENT NUMBER: 142:23188
TITLE: A preparation of fluoromethanesulfonyl-substituted cycloalkanoindole derivatives, useful as prostaglandin d2 antagonists
INVENTOR(S): Li, Lianhai; Beaulieu, Christian; Guay, Daniel; Sturino, Claudio; Wang, Zhaoyin
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103970	A1	20041202	WO 2004-CA752	20040518

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-471957P P 20030520
OTHER SOURCE(S): MARPAT 142:23188
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of fluoromethanesulfonyl-substituted cycloalkanoindole derivs. of formula I [wherein: X is (CH2)1-2; R1 is alkyl optionally substituted with 1 to 5 halogens], useful as prostaglandin d2 antagonists (no biol. data). For instance, cyclopentaindolylacetic acid derivative II was prepared via N-benzylation of indole derivative III by (1R)-1-(4-chlorophenyl)ethanol and subsequent hydrolysis.

IT **794535-38-9P 800376-96-9P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of fluoromethanesulfonyl-substituted cycloalkanoindole derivs. useful as prostaglandin d2 antagonists)
RN 794535-38-9 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 9-[(1S)-1-(4-chlorophenyl)ethyl]-6-fluoro-2,3,4,9-tetrahydro-8-(methylsulfonyl)-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800376-96-9 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-[(1S)-1-(4-chlorophenyl)ethyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **800376-93-6P 800376-97-0P 800376-98-1P**
800377-01-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fluoromethanesulfonyl-substituted cycloalkanoindole derivs. useful as prostaglandin d2 antagonists)
RN 800376-93-6 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-[(1S)-1-(4-chlorophenyl)ethyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, sodium salt, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 800376-97-0 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 9-[(1S)-1-(4-chlorophenyl)ethyl]-6-fluoro-2,3,4,9-tetrahydro-8-(methylsulfonyl)-, sodium salt, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 800376-98-1 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 9-[(1R)-1-(4-chlorophenyl)-2-fluoroethyl]-6-fluoro-2,3,4,9-tetrahydro-8-(methylsulfonyl)-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 800377-01-9 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 9-[(1R)-1-(4-chlorophenyl)-2,2-difluoroethyl]-6-fluoro-2,3,4,9-tetrahydro-8-(methylsulfonyl)-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:999670 HCAPLUS
DOCUMENT NUMBER: 141:420447
TITLE: Method of treating atherosclerosis, dyslipidemias and related conditions
INVENTOR(S): Cheng, Kang; Waters, M. Gerard; Metters, Kathleen M.; O'Neill, Gary
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 33 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2004229844	A1	20041118	US 2004-844773	20040513
WO 2004103370	A1	20041202	WO 2004-US14980	20040513

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-470665P P 20030515

AB A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent or eliminate flushing that may otherwise occur.

IT **571170-77-9P 571170-79-1P 571170-95-1P**
794535-32-3P 794535-38-9P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(method of treating atherosclerosis, dyslipidemias and related conditions)

RN 571170-77-9 HCAPLUS

CN Cyclopent[b]indole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 571170-79-1 HCAPLUS

CN 1H-Carbazole-1-acetic acid, 9-[(4-chlorophenyl)methyl]-6-fluoro-2,3,4,9-tetrahydro-8-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 571170-95-1 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-1-oxo-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 794535-32-3 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-[1-(4-chlorophenyl)ethyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 794535-38-9 HCAPLUS

CN 1H-Carbazole-1-acetic acid, 9-[(1S)-1-(4-chlorophenyl)ethyl]-6-fluoro-2,3,4,9-tetrahydro-8-(methylsulfonyl)-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **572874-50-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(method of treating atherosclerosis, dyslipidemias and related conditions)
RN 572874-50-1 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, sodium salt, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **794535-43-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(method of treating atherosclerosis, dyslipidemias and related conditions)
RN 794535-43-6 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 9-[1-(4-chlorophenyl)ethyl]-6-fluoro-2,3,4,9-tetrahydro-8-(methylsulfonyl)-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:591147 HCAPLUS
DOCUMENT NUMBER: 139:149524
TITLE: Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment using them
INVENTOR(S): Berthelette, Carl; Lachance, Nicolas; Li, Lianhai; Sturino, Claudio; Wang, Zhaoyin
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062200	A2	20030731	WO 2003-CA84	20030122
WO 2003062200	A3	20031204		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003158246	A1	20030821	US 2003-348403	20030121
CA 2471952	AA	20030731	CA 2003-2471952	20030122
BR 2003007050	A	20041026	BR 2003-7050	20030122
EP 1470107	A2	20041027	EP 2003-700740	20030122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005124680	A1	20050609	US 2003-502380	20030122
JP 2005518413	T2	20050623	JP 2003-562082	20030122
PRIORITY APPLN. INFO.:			US 2002-351384P	P 20020124
			WO 2003-CA84	W 20030122

OTHER SOURCE(S): MARPAT 139:149524
GI



I



II

AB Fluoro substituted cycloalkanoindole derivs. I [X1 = (O)n; X2 = (CH2)m; n = 0, 1; m = 1 - 3; R1 = H, C1-3-alkyl, C1-3-haloalkyl, cyclopropyl; R2 = C6H4Cl-4, C6H2Cl3-2,4,6], their enantiomers and pharmaceutically acceptable salts, are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases. Thus, (-)-cyclopentanoindole II was prepared via cyclocondensation of 4-F-2-IC6H3NH2 with Et 2-(2-oxocyclopentyl)acetate, saponification, regioselective bromination, N-alkylation with 4-ClC6H4CH2Br, resolution with (S)-(-)-1-(1-naphthyl)ethylamine, esterification with diazomethane, sulfonylation with MeSO2Na and ester hydrolysis. The binding activity of I for prostaglandin receptors was determined (no data).

IT **571170-77-9P 571170-78-0P 571170-79-1P 571170-80-4P 571170-81-5P 571170-82-6P 571170-95-1P 572874-50-1P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and prostaglandin receptor binding activity of fluoro substituted cycloalkanoindoles)

RN 571170-77-9 HCAPLUS

CN Cyclopent[b]indole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 571170-78-0 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-[(1R)-1-(4-chlorophenyl)ethyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 571170-79-1 HCAPLUS
CN 1H-Carbazole-1-acetic acid, 9-[(4-chlorophenyl)methyl]-6-fluoro-2,3,4,9-tetrahydro-8-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 571170-80-4 HCAPLUS

CN Cyclopent[b]indole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-1-oxo- (9CI) (CA INDEX NAME)



RN 571170-81-5 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 571170-82-6 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-[(1R)-1-(4-chlorophenyl)ethyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 571170-95-1 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-1-oxo-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 572874-50-1 HCAPLUS
CN Cyclopent[b]indole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, sodium salt, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● Na

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	36.99	386.97

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.38	-7.30

STN INTERNATIONAL LOGOFF AT 13:02:40 ON 21 OCT 2005